AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$LQDA

Saggar Rajeev sold $6.0M of LQDA

Saggar Rajeev (Chief Medical Officer) sold 79,534 shares of Liquidia Corp (LQDA) at an average of $75.09 ($74.06–$76.84, $5.97M total) across 2 trades over 2026-08-17 to 2026-08-19.

Original reporting
SEC EDGAR · Saggar Rajeev
Published Aug 19, 2026, 10:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The insider sale provides fresh data on insider sentiment, which traders may use to adjust short-term positions.

02

Market read

New insider sale information for a small-cap biotech, modest relevance for traders tracking insider activity.

03

What to watch

No accompanying corporate news; the sale may be routine and not indicative of future performance.

Relevance 6/10Novelty 6/10Timing: filed Aug 19, 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Medical Officer Saggar Rajeev sold 79,534 shares for $5.97M, reducing his stake to 142,265 shares.

Expected impact

Possible modest downside pressure in the near term.

Evidence & confidence

CMO is a senior insider; a $6M sale is material for a small-cap biotech, but not large enough to trigger a major move.

Market effects

Sector

May raise concerns for biotech sector investors monitoring insider activity.

Regional

Limited to U.S. biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be unrelated to confidence, perhaps for personal financial planning.

Key entities

  • Company
    Liquidia Corp

    Biopharmaceutical company developing drug delivery platforms.

  • Individual
    Saggar Rajeev

    Chief Medical Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

AUG 31
$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

tradingview.com2 min
AUG 19
$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

fool.com3 min
AUG 13
$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

tradingview.com7 min
AUG 12
$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient

SEC EDGAR 8-K6 min